BC Innovations | Dec 10, 2019
Emerging Company Profile

Zentalis debuts with trio of clinical oncology programs, $85M series C

Zentalis emerged from stealth Monday with an untranched and oversubscribed $85 million series C and three internally discovered clinical cancer candidates, with plans to begin pivotal testing by 2021. The C round syndicate includes Matrix...
BC Extra | Sep 26, 2019
Politics & Policy

MNCs gain ground in China’s centralized procurement

Five multinational originator companies were among the winning bidders in China’s national expansion of its centralized procurement program for generic and off-patent drugs in a process that saw steep price cuts and more robust participation...
BC Week In Review | Sep 20, 2019
Company News

China exempts 12 cancer drugs from tariffs

China is exempting 12 cancer drugs from tariffs imposed on U.S. goods, the first time China has offered tariff relief since the trade war began last year. The 12 drugs include Iressa gefitinib and Tomudex...
BioCentury | Sep 14, 2019
Product Development

Success in lung cancer niches will hinge on access to next-gen sequencing

New targeted lung cancer therapies against RET, KRAS and c-MET are all outperforming standard of care in the clinic, including checkpoint inhibitors. But whether these therapies see uptake will likely depend more on whether next-generation...
BC Extra | Sep 5, 2019
Politics & Policy

China moves to take centralized procurement nationwide

China's Joint Procurement Office will expand its pilot program for centralized procurement of generic and off-patent originator drugs nationwide, a move that could further cut prices of the 25 drugs in the program. Under the...
BC Innovations | Aug 23, 2019
Distillery Therapeutics

KRAS inhibitor combinations for improved therapeutic efficacy

DISEASE CATEGORY: Cancer INDICATION: Lung cancer, pancreatic cancer UCSF’s Kevan Shokat and colleagues have identified two sets of genes for which inhibition could improve the efficacy of KRAS G12C inhibitors. Through a CRISPR-based screen in...
BC Extra | Aug 9, 2019
Clinical News

AZ notches another win in cancer with Tagrisso in NSCLC

AstraZeneca continued its momentum of positive cancer news this summer as Tagrisso osimertinib showed a survival benefit in first-line NSCLC. AstraZeneca plc (LSE:AZN; NYSE:AZN) said the oral irreversible inhibitor of EGFR activating mutations significantly improved...
BioCentury | Jun 19, 2019

Why China’s 4 + 7 policy is good news for innovative drug developers

China’s new policy on generic drugs is likely to have knock-on benefits for drug developers aiming to bring innovative compounds to the China market. For multinationals, it will come after some pain, as they’ll see...
BioCentury | May 24, 2019
Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

FDA's ODAC may have given the thumbs down to Daiichi’s quizartinib, but a stocked pipeline and another ongoing trial of the candidate suggest it’s more of a hiccup than a hurdle in the Japanese pharma’s...
BC Innovations | Apr 22, 2019
Distillery Therapeutics

Combined inhibition of EGFR and RAF1 for mutant-KRAS, mutant TP53-driven PDAC

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Cell culture and mouse studies suggest dual inhibition of EGFR and CRAF could help treat KRAS- and p53-mutant pancreatic ductal adenocarcinoma (PDAC). In nine patient-derived KRAS- and p53-mutant PDAC...
Items per page:
1 - 10 of 370